PSMA与mpMRI定位前列腺癌主病灶的病理一致性及微推量启示
单中心回顾分析48例前列腺癌术前PSMA与mpMRI影像与术后病理对照,病理主病灶与大病灶同侧半腺符合率PSMA为94%、mpMRI为90%,但两者分别有59%和64%低估病灶大小,PSA较高与影像病理尺寸差异更大相关。
要点
- PSMA和mpMRI主病灶半腺定位与病理符合率分别达94%和90%。
- PSMA和mpMRI分别有59%和64%低估病理病灶大小。
- PSA较高与PSMA及mpMRI影像病理尺寸差异更大相关。
核心结论
- 标准治疗边界可能高估或低估真实大体病灶范围,取决于个体肿瘤特征。
- 需进一步研究建立PSMA和mpMRI引导微推量的标准化框架。
研究设计与样本
- 单中心回顾性分析,纳入2022年1月至2023年12月术前行PSMA影像后接受前列腺切除术的前列腺癌患者48例。
- PSMA病灶由对最终病理不知情的阅片者独立勾画和测量,mpMRI报告回顾病灶数目、位置和大小,并与最终病理比较。
主要发现
- 48例患者平均(SD)PSA为13.9(±12.9),40%为grade group 4/5,58%为pT3或更高。
- 病理主病灶与最大PSMA/mpMRI病灶同侧半腺符合率分别为94%/90%。
- PSMA与mpMRI和最终病理的中位最大病灶直径差异分别为3.4 mm(IQR,16.3-24.8)和4 mm(IQR,3-9)。
- PSMA和mpMRI分别有59%和64%的病例低估病灶大小。
- PSMA上较高PSA和较低活检grade group与更大的影像/病理尺寸差异相关(单变量和多变量调整SUVmax后);mpMRI上较高PSA与更大尺寸差异相关(单变量和多变量调整PI-RADS评分后,P < .05)。
临床怎么用
- 基于PSMA或mpMRI勾画前列腺癌主病灶行微推量时,应意识到影像可能低估真实病灶大小。
- PSA较高或活检grade group较低的患者,影像与病理尺寸差异可能更大,需谨慎设定边界。
局限性
- 单中心回顾性分析,样本量48例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA) positron emission tomography and multiparametric magnetic resonance imaging (mpMRI) are used to contour the dominant intraprostatic lesion (DIL) when incorporating a microboost. However, it is unclear how well PSMA and mpMRI findings correlate with the true pathologic DIL. So, we performed an analysis between preoperative imaging and the final surgical specimen to identify predictors of discordance. METHODS AND MATERIALS: This was a single-center retrospective analysis of patients with prostate cancer who underwent PSMA imaging before prostatectomy between January 2022 and December 2023. PSMA lesions were independently contoured and measured by a reviewer blinded to the final pathology. mpMRI reports were reviewed for lesion number, location, and size. Lesion size and hemigland location on imaging were compared to the final pathology. Associations between concordance or discordance and patients' demographics and clinicopathological characteristics were examined. RESULTS: Of the 48 patients included, mean (SD) PSA was 13.9 (±12.9), 40% had grade group 4/5 disease, and 58% were staged as pT3 or higher. The pathologic DIL matched the hemigland of the largest PSMA/mpMRI lesion in 94/90% of cases, respectively. The median maximum lesion diameter size discrepancy between PSMA and mpMRI and final pathology was 3.4 mm (IQR, 16.3-24.8) and 4 mm (IQR, 3-9), respectively. PSMA and mpMRI underestimated lesion size in 59% and 64% of cases, respectively. On PSMA, higher prostate-specific antigen (PSA) and lower biopsy grade groups were associated with greater imaging/pathology size discrepancy on both univariate and multivariable analysis after adjusting for maximum standardized uptake volume (SUVmax); on mpMRI, higher PSA was associated with greater imaging/pathology size discrepancy on both univariate and multivariable analysis after adjusting for prostate imaging reporting and data system (PI-RADS) score (P < .05). CONCLUSION: Standard treatment margins may either overestimate or underestimate the extent of the true gross disease, depending on individual tumor characteristics. Further research is needed to develop a standardized framework for using PSMA and mpMRI to guide microboosting.
引用
- Farmer A, Ballas LK, Sandler HM, et al. Implications for Radiation Microboosting Based on Pathology Correlations With Prostate-Specific Membrane Antigen and Multiparametric Magnetic Resonance Imaging Findings. Adv Radiat Oncol. 2026. PMID: 41907067. doi:10.1016/j.adro.2026.102010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。